Paper Details

  1. Home
  2. Paper Details

[Pharmacokinetics and -dynamics of retard formation of isradipine. Summary of studies].

Author: HirschbergerR

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
English AbstractA summary of a research paper/publication written in English for a wider audience.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A sustained-release form of isradipine showed a 22.5% increase in bioavailability compared to the standard formulation. Peak plasma levels were reached 5-7 hours after oral administration and remained stable. Bioavailability and peak plasma levels increased linearly with dosage. At therapeutic doses, isradipine did not accumulate, and plasma levels remained at half the maximum 24 hours after ingestion. The sustained-release version had fewer side effects due to slower absorption and minimal concentration fluctuations.
Paper Details　
Original Abstract of the Article :
The newly developed sustained-release form of isradipine (Vascal uno/Lomir SRO) releases the active substance continuously from a gel matrix over a period of 24 hours. In comparison with the standard formulation, the absolute bioavailability of the sustained-release preparation is somewhat increased...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8258429

データ提供：米国国立医学図書館（NLM）

Sustained Release Isradipine: A New Approach for Treating Hypertension

The study investigates the pharmacokinetic and pharmacodynamic properties of a new sustained-release formulation of isradipine, a medication used to treat hypertension. The authors explore the benefits of this extended-release formulation in terms of bioavailability, drug levels in the blood, and side effects.

Sustained Release Isradipine: A Consistent Approach to Managing Hypertension

The study demonstrates the effectiveness of the sustained-release formulation of isradipine, showcasing a more consistent delivery of the drug over a 24-hour period, potentially leading to improved blood pressure control and reduced side effects.

Beyond the Pill: Finding the Right Approach to Manage Hypertension

The study highlights the importance of finding the most effective and tolerable treatment options for patients with hypertension. The sustained-release formulation of isradipine could potentially offer a valuable alternative for those seeking a more consistent approach to managing their condition.

Dr.Camel's Conclusion

Imagine a desert where a constant supply of cool water is available, keeping the thirsty traveler hydrated. This study explores a new way to deliver isradipine, potentially offering patients with hypertension a more consistent and reliable source of relief from their condition.

Date :
  1. Date Completed 1994-01-19
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8258429

DOI: Digital Object Identifier

8258429

Related Literature

Article Analysis
・Side Effects of isradipine
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.